The molecular drug developer received funding from investors including GlaxoSmithKline, MRL Ventures Fund and GV in a Fidelity-led series C round.

US-based small molecule drug developer LifeMine Therapeutics closed a $175m series C round yesterday featuring internet and technology conglomerate Alphabet and pharmaceutical firms Merck & Co and GlaxoSmithKline.

The round was led by investment and financial services group Fidelity Management & Research and included Arch Venture Partners, Blue Pool Capital, Invus and 3W Partners Capital, while Merck and Alphabet invested through MRL Ventures Fund and GV respectively.

Founded in 2017, LifeMine is developing a drug discovery platform called Avatar-Rx which…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn